High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

Paul G. Richardson(Harvard University), Kenneth C. Anderson(Dana-Farber Cancer Institute), Carolyn Revta(Dana-Farber Cancer Institute), Constantine S. Mitsiades(Dana-Farber Cancer Institute), Dixil Francis(Emory University), Irene M. Ghobrial(Dana-Farber Cancer Institute), Sagar Lonial(Emory University), Sundar Jagannath(Mount Sinai Hospital), Robin Joyce(Beth Israel Deaconess Medical Center), Kate Ittleman(Dana-Farber Cancer Institute), Nikhil C. Munshi(Dana-Farber Cancer Institute), Carol Delaney(Beth Israel Deaconess Medical Center), C. Leister(University of Michigan), Jacob P. Laubach(Harvard University), Robert Knight(King's College London), Deborah Doss(Dana-Farber Cancer Institute), Noopur Raje(Massachusetts General Hospital), David Avigan(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Andrzej Jakubowiak(University of Chicago Medical Center), Wanling Xie(Dana-Farber Cancer Institute), Teru Hideshima(Harvard University), Amitabha Mazumder(NYU Langone Health), Robert Schlossman(University of Leeds), Diane Warren(Dana-Farber Cancer Institute), Sarah Kaster(Massachusetts General Hospital), David H. Vesole(Hackensack University Medical Center), Edie Weller(Boston Children's Hospital), Dixie-Lee Esseltine(Millennium Engineering and Integration (United States)), Marisa Lauria(Beth Israel Deaconess Medical Center)

Blood

November 20, 2009

Cited by 8

Related Papers

|Nature|2013|10.1k

|Nature Medicine|2020|2.7k

|New England Journal of Medicine|2003|2.6k

|Leukemia|2006|2.6k

|Journal of Clinical Oncology|2015|2.2k